KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer.

Isamu Okamoto, Shoichi Kuyama, Nicolas Girard, Shun Lu, Fábio Franke, Ziming Li, Pongwut Danchaivijitr, Ji-Youn Han, Jong-Mu Sun, Shunichi Sugawara, Edward Pan, Natalie Ren, Aiying Chen, Rachana Rajagopalan, Aaron E Lisberg

Future Oncol 20(37) 2927-2936

PMID39469838
PMCIDPMC11572237
DOI10.1080/14796694.2024.2409621
发表日期2024-10-29
摘要

摘要

For patients with advanced/metastatic non-small-cell lung cancer (NSCLC) without actionable genomic alterations and low (<50%) PD-L1 expression, pembrolizumab plus pemetrexed and platinum chemotherapy is a preferred first-line treatment. These patients have comparatively worse outcomes than those with higher PD-L1 expression, underscoring the need for new combination strategies. Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, has demonstrated encouraging antitumor activity and safety in this patient population. We describe the rationale and design of TROPION-Lung07, a randomized, open-label Phase III study assessing Dato-DXd in combination with pembrolizumab with/without platinum-based chemotherapy versus pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with advanced/metastatic non-squamous NSCLC without actionable genomic alterations and <50% PD-L1 expression. Primary study objectives are progression-free survival and overall survival.Clinical Trial Registration: NCT05555732 (ClinicalTrials.gov).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。